PMID- 18076360
OWN - NLM
STAT- MEDLINE
DCOM- 20080514
LR  - 20161018
IS  - 1434-6621 (Print)
IS  - 1434-6621 (Linking)
VI  - 46
IP  - 2
DP  - 2008
TI  - Long-term prognostic value of mid-regional pro-adrenomedullin and C-terminal 
      pro-endothelin-1 in patients with acute myocardial infarction.
PG  - 204-11
AB  - BACKGROUND: Mid-regional pro-adrenomedullin (MR-proADM) and endothelin-1 have 
      been shown to predict mortality of patients with acute myocardial infarction. 
      However, the prognostic value of both biomarkers in predicting long-term clinical 
      events after acute myocardial infarction remains unclear. METHODS: In a 
      prospective study, 30 patients suffering from acute ST elevation myocardial 
      infarction or non-ST elevation myocardial infarction were enrolled. Measurements 
      of MR-proADM and CT-pro-endothelin-1 (CT-proET-1) were performed at initial 
      presentation, 2 or 3 days and 4 months after acute myocardial infarction. 
      Long-term clinical events (e.g., recurrent myocardial infarction, percutaneous 
      transluminal coronary angioplasty, aorto-coronary venous bypass or cardiogenic 
      shock) were documented over a period from the 4th until the 10th month. RESULTS: 
      Both MR-proADM and CT-proET-1 were able to differentiate patients with subsequent 
      long-term clinical events (n=11) from those without (n=19). At the time of acute 
      myocardial infarction, median MR-proADM level of the event group was 0.69 nmol/L 
      as compared to 0.59 nmol/L of the no-event group (p=0.036). A difference was 
      still observed after 3 days (event group median 0.66 nmol/L; no-event group 
      median 0.57 nmol/L; p=0.022). Accordingly, median CT-proET-1 level was 72.9 
      pmol/L in the event group as compared to a median of 54.4 pmol/L in patients in 
      the no-event group (p=0.009) 3 days after acute myocardial infarction. Within the 
      acute phase, patients with MR-proADM levels > or =0.67 nmol/L were 3 times more 
      likely (relative risk 2.8; 95% confidence interval 1.2-6.9; p=0.042) to suffer 
      from a future clinical event. The area under the curve (AUC) was 0.71 (95% 
      confidence interval 0.51-0.86; p=0.046). After 3 days, patients with CT-proET-1 
      levels > or =57 pmol/L were 6 times more likely (relative risk 5.9; 95% 
      confidence interval 0.9-40.4; p=0.036) to suffer from a future clinical event. 
      The AUC was 0.76 (95% confidence interval 0.55-0.90; p=0.015). CONCLUSIONS: 
      Elevated levels of MR-proADM and CT-proET-1 during the acute phase of myocardial 
      infarction may predict an adverse long-term clinical outcome.
FAU - Behnes, Michael
AU  - Behnes M
AD  - 1First Department of Medicine, Faculty of Medicine Mannheim, University of 
      Heidelberg, Mannheim, Germany.
FAU - Papassotiriou, Jana
AU  - Papassotiriou J
FAU - Walter, Thomas
AU  - Walter T
FAU - Fiedler, Esther
AU  - Fiedler E
FAU - Sauer, Tamara
AU  - Sauer T
FAU - Lang, Siegfried
AU  - Lang S
FAU - Elmas, Elif
AU  - Elmas E
FAU - Hoffmann, Ursula
AU  - Hoffmann U
FAU - Borggrefe, Martin
AU  - Borggrefe M
FAU - Brueckmann, Martina
AU  - Brueckmann M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Clin Chem Lab Med
JT  - Clinical chemistry and laboratory medicine
JID - 9806306
RN  - 0 (Endothelin-1)
RN  - 148498-78-6 (Adrenomedullin)
SB  - IM
MH  - Adrenomedullin/*blood
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Endothelin-1/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/blood/*diagnosis
MH  - Prognosis
MH  - Prospective Studies
EDAT- 2007/12/14 09:00
MHDA- 2008/05/15 09:00
CRDT- 2007/12/14 09:00
PHST- 2007/12/14 09:00 [pubmed]
PHST- 2008/05/15 09:00 [medline]
PHST- 2007/12/14 09:00 [entrez]
AID - 10.1515/CCLM.2008.040 [doi]
PST - ppublish
SO  - Clin Chem Lab Med. 2008;46(2):204-11. doi: 10.1515/CCLM.2008.040.